Claims for Patent: 10,973,806
✉ Email this page to a colleague
Summary for Patent: 10,973,806
Title: | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Abstract: | The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin. |
Inventor(s): | Desai; Neil P. (Pacific Palisades, CA) |
Assignee: | Abraxis BioScience, LLC (Summit, NJ) |
Application Number: | 15/737,936 |
Patent Claims: |
1. A method of treating a malignant perivascular epithelioid cell tumor (PEComa) in an individual, comprising intravenously administering to the individual an effective
amount of a composition comprising nanoparticles comprising sirolimus and an albumin, wherein the effective amount of sirolimus in the nanoparticle composition is about 56 mg/m.sup.2 to about 100 mg/m.sup.2, and wherein the nanoparticle composition is
administered on days 1 and 8 of a 21-day cycle.
2. The method of claim 1, wherein the PEComa is selected from the group consisting of a pulmonary clear cell `sugar` tumor, and a PEComa not otherwise specified (PEComa-NOS). 3. The method of claim 1, wherein the PEComa is locally advanced, metastatic, or recurrent. 4. The method of claim 1, wherein the nanoparticles in the composition have an average diameter of no greater than about 150 nm. 5. The method of claim 1, wherein sirolimus in the nanoparticles is coated with the albumin. 6. The method of claim 1, wherein the weight ratio of albumin and sirolimus in the nanoparticle composition is about 1:1 to about 9:1. 7. The method of claim 1, wherein the albumin is human albumin. 8. The method of claim 7, wherein the albumin is human serum albumin. 9. The method of claim 1, wherein the individual is human. 10. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 100 mg/m.sup.2. 11. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 75 mg/m.sup.2. 12. The method of claim 1, wherein the effective amount of sirolimus in the nanoparticle composition is about 56 mg/m.sup.2. |